Tag: Cognito
Cognito announces OVERTURE II results indicating durable effects of Spectris treatment...
Cognito Therapeutics has announced treatment results from OVERTURE II—an open-label extension (OLE) study of Spectris, the company’s potential disease-modifying therapy for the treatment of...
Cognito announces 18-month data showing durability of gamma sensory stimulation for...
Cognito Therapeutics has announced that continued active treatment with the company’s gamma sensory stimulation technology in the Phase 2 OVERTURE open label extension (OLE)...
Cognito presents MRI data showing efficacy of non-invasive gamma stimulation therapy...
Cognito Therapeutics has announced “robust, lobe-specific” changes in white matter volume and myelination in Alzheimer’s disease patients following six months of non-invasive gamma stimulation...
Cognito announces first patient enrolment in US pivotal study of novel...
Cognito Therapeutics has announced the first patient enrolment in its US pivotal study, HOPE, which is designed to demonstrate the safety and efficacy of...
